The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
MDS 2023 | Benefits, applicability & uses of the IPSS-M in MDS
Austin Kulasekararaj, MBBS, MD, MRCP, FRCPath, King’s College Hospital NHS Foundation Trust, London, UK, discusses the advantages and uses of the novel IPSS-Molecular (IPSS-M) prognostic scoring system for myelodysplastic syndromes (MDS), explaining that its applicability might be limited in countries with reduced access to mutation testing. This interview took place at the 17th International Congress on Myelodysplastic Syndromes 2023 (MDS 2023) held in Marseille, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
